ArticleOncotarget2021

The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.

Aditya Kulkarni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.